Abstract: The present disclosure provides methods, devices, systems and kits for producing polymeric microbeads, including lanthanide-encoded microbeads. Among others, the present disclosure provides methods, systems and kits for producing functionalized microbeads that include on their surfaces amphipathic moieties with free reactive groups that remain free and can be used for covalently coupling molecules or moieties of inters to the microbeads.

Abstract: The present disclosure relates to a light-driven system which is able to chemically modify an organic substrate with high efficiency and in a cost-effective manner. Also provided are methods for chemically modifying an organic substrate using the present systems and methods for manufacturing such systems.

Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Abstract: A device for generating individual photons with energy E includes quantum emitters, having at least one determined transition with the energy E from an energy level N* to a lower energy level N1. The emitters are near a propagation path running from first to second regions. The device also includes at least one light source to output light, for propagation along the path. The light has the energy E for resonant excitation of the energy level N*. The emitters are arranged so that optionally exactly Z emitters are illuminated, forming an optical thickness ?>0 for the light along the path. The number Z lies in a range of Z0±10% and Z0 is a number at which a maximum destructive interference in the second region occurs between a two-photon component of the light scattered on the ZO emitters and a two-photon component of the non-scattered light.

Abstract: The present disclosure relates to a system for generating a predefined electrical signal in an MR scanner for use in electrical stimulation of a subject during MRI or functional MRI of said subject, wherein said MR scanner is located inside a shielded MRI room. The system comprises a control unit to be located outside the MRI room for generating an electrical signal and an electrical to optical converter to be located outside the MRI room for converting said electrical signal to a corresponding optical signal. An optical transmitting element, such as an optical fiber, is used for transmitting the optical signal into the MRI room, and an optical to electrical converter is used for converting the optical signal to said predefined electrical signal for electrical stimulation of the subject during magnetic resonance imaging. The optical to electrical converter is configured for being located inside the MRI room and for operation during magnetic resonance imaging.

Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.

Abstract: Disclosed is a method for controlling a biofilm, for removing a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process including cellulosic fibre material. In the method, a composition including a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2-propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.

Abstract: A device for generating individual photons with energy E includes quantum emitters, having at least one determined transition with the energy E from an energy level N* to a lower energy level N1. The emitters are near a propagation path running from first to second regions. The device also includes at least one light source to output light, for propagation along the path. The light has the energy E for resonant excitation of the energy level N*. The emitters are arranged so that optionally exactly Z emitters are illuminated, forming an optical thickness ?>0 for the light along the path. The number Z lies in a range of ZO±10% and ZO is a number at which a maximum destructive interference in the second region occurs between a two-photon component of the light scattered on the ZO emitters and a two-photon component of the non-scattered light.

Abstract: The present disclosure relates to compositions comprising insulin and to be administered rectally for treatment of inflammatory bowel diseases and inflammation-induced colorectal tumour and/or cancer.

Abstract: The present invention relates to virally expressed peptides with high affinity for the PDZ domains, such as the PDZ domain of PICK1. The invention furthermore relates to the therapeutic use of these peptides in prevention and/or treatment of diseases and/or disorders associated with maladaptive plasticity and/or transmission.

Abstract: The present disclosure relates to a method of inducing weight loss and/or preventing weight gain in a subject affected by administering certain diets selected based on the fasting blood glucose and/or the fasting insulin of the subject. The present disclosure further provides personalized dietary instruction, based on the fasting blood glucose and/or the fasting insulin of a subject, with the potential to improve the weight loss and prevent weight regain. The present disclosure further relates to methods for predicting weight loss success and classifying responsiveness of a subject to a certain diet as well as methods for selecting a weight loss or a weight gain diet for a subject based on the fasting blood glucose and/or the fasting insulin of the subject.

Abstract: Mirtazapine is useful for the treatment and/or prophylaxis of medication overuse headache based on tension-type headache. Moreover, a pharmaceutical composition and/or the use of mirtazapine for the manufacture of a medicament, are useful against medication overuse headache based on tension-type headache, and the treatment of medication overuse headache based on tension-type headache.

Abstract: The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The invention furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.

Abstract: The invention relates to a virus like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, asthma, and/or allergy diseases/disorders.

Abstract: The invention relates to methods for preparing a beverage comprising at least 2 g/L ?-glucan, wherein said ?-glucans have an average molecular weight in the range of 80 to 200 kDa. The methods involve mashing barley kernels comprising at least 10% ?-glucans and having a ratio of DP3/DP4 in said ?-glucan of at least 3 in the presence of ?-amylase and endo-1,3(4)-?-glucanase activity. The beverages have a viscosity providing a good mouth-feel, and at the same time they comprise ?-glucans, which are able to aid in lowering LDL cholesterol levels. The beverages are generally stable and can be stored for months at room temperature without a significant decrease in ?-glucan content.

Abstract: The present invention relates to mutant Cpf1 endonucleases having altered activity compared to the wild type Cpf1, and their use to introduce single strand breaks in nucleic acid sequences. Methods for detection and quantification of a nucleic acid sequence are also disclosed. Methods for diagnosis of an infectious disease are also disclosed.

Abstract: The present invention relates to a method for generating glucose-responsive beta cells.

Abstract: Disclosed is a method for controlling a biofilm, for removing a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process including cellulosic fibre material. In the method, a composition including a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2-propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.

Abstract: The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12-R23 and act by preventing or disrupting the binding of the H4 tail K12-R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket.

Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.